



**CONTACT:**

Tara Charvat  
Valeritas, Inc.  
908-927-9920 x20110  
TCharvat@valeritas.com

**Valeritas Announces Appointment of New CFO**  
- Former Amicus Therapeutics Chief Financial Officer  
James E. Dentzer Joins Executive Team -

---

**Bridgewater, N.J., March 15, 2010** – Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that it has hired James E. Dentzer to serve as its Chief Financial Officer.

Dentzer brings a wealth of experience to Valeritas, with his most recent success as Chief Financial Officer of Amicus Therapeutics where he led the company in closing a Series D private financing and executing a successful IPO.

“We are extremely pleased to welcome Jim to the Valeritas executive team,” said Kristine Peterson, Chief Executive Officer, Valeritas. “He brings the financial experience Valeritas needs as we continue to advance the development of our products. This is an exciting stage in our company’s growth and Jim’s strong track record for taking companies public, helping organizations finance their growth, and his proven commercialization experience makes him ideal for our organization.”

“Joining Valeritas at this important time is very exciting,” said Dentzer. “With the company’s strong set of current investors committed to the company’s organizational needs, Valeritas is positioned to be a major player in the diabetes space. I am proud to

have joined an organization that can provide life-changing therapeutic options to people suffering with this condition.”

Dentzer joined Amicus Therapeutics as Chief Financial Officer in October 2006 where he supported the organization through its IPO. Prior to joining Amicus, he was Vice President and Corporate Controller of Biogen Idec and held various senior financial roles at E.I. du Pont de Nemours and Company.

**About Valeritas, Inc.**

Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas’ medical technologies portfolio is headlined by the h-Patch™ technology. The first use of the h-Patch™ technology will be the V-Go™ Disposable Insulin Delivery Device for the simple delivery of basal-bolus therapy via a preset basal rate and on-demand bolus dosing around mealtimes.

In addition to the V-Go™, Valeritas’ delivery technology portfolio includes the h-Patch™ for the delivery of other compounds beyond insulin, the Mini-Ject™ Pre-Filled Needle-Free Delivery System, and the Micro-Trans™ Microneedle Transdermal Delivery Patch. These technologies, when combined with certain compounds, are designed to provide unique products that allow precise dosing in previously difficult to treat conditions.

Headquartered in Bridgewater, N.J., Valeritas operates its R&D and manufacturing in a state-of-the-art facility in Shrewsbury, Massachusetts. Valeritas primary investors include: MPM Capital, Pitango Venture Capital, Abingworth, US Venture Partners, Onset Ventures, Advanced Technology Ventures, HLM Venture Partners, CHL Medical Partners, and Kaiser Permanente Ventures.